Best for Liver Health

Tesamorelin demonstrates strong efficacy for reducing liver fat and preventing fibrosis progression in HIV-associated fatty liver disease across multiple well-designed human RCTs. Evidence is robust but primarily limited to the HIV population with NAFLD/MASLD.

GLP-1 receptor agonists, particularly semaglutide at 2.4 mg/week, demonstrate strong efficacy in improving liver histology and reducing steatosis in humans with MASH and metabolic dysfunction-associated steatotic liver disease, with consistent results across multiple phase 2/3 RCTs and meta-analyses. However, efficacy in reversing advanced fibrosis remains limited.

Probiotics demonstrate strong evidence for improving liver health markers in humans, particularly for nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Multiple meta-analyses of RCTs show consistent reductions in liver enzymes (ALT, AST) and inflammatory markers, with specific probiotic combinations identified as most effective.

Thymosin alpha-1 shows probable efficacy for chronic hepatitis B and HCC-related outcomes in multiple human studies, with consistent immune-enhancing and modest antiviral effects. However, evidence is limited by small-to-moderate sample sizes, heterogeneous study designs, and lack of large-scale RCTs demonstrating definitive superiority over standard treatments.

LL-37 shows probable protective effects in liver disease based on multiple human observational studies and animal models, with evidence for anti-inflammatory and regenerative mechanisms. However, no large-scale human RCTs exist, and most mechanistic evidence comes from animal models or cell culture.

Melanotan 1 (afamelanotide) demonstrates probable protective effects on liver function in erythropoietic protoporphyria patients based on multiple human observational studies, but evidence is limited to a specific disease context with no RCT data for general liver health.

Thymalin shows probable benefit for liver health through immunomodulation in 2-3 human observational studies, but evidence is limited by lack of RCTs, small samples, and primarily indirect measures of liver function rather than direct hepatic outcomes.

Omega-3 fatty acids show probable efficacy for liver health, particularly in reducing liver enzyme markers and hepatic steatosis in NAFLD patients. Evidence derives primarily from small human RCTs and numerous animal studies, with consistent mechanistic support but limited large-scale human replication.

Magnesium supplementation shows probable benefit for liver health, particularly in nonalcoholic fatty liver disease (NAFLD), with multiple human RCTs and observational studies demonstrating improvements in liver enzymes and hepatic steatosis. However, evidence is limited by small sample sizes, short intervention durations, and inconsistent dosing protocols.

NAC demonstrates proven efficacy for acetaminophen-induced liver injury in humans with strong evidence from meta-analysis and RCTs, but evidence for other liver conditions (NAFLD, NASH, viral hepatitis) remains preliminary or inconsistent. NAC works through antioxidant mechanisms, but clinical benefit outside acetaminophen toxicity is not yet conclusively established.

Vitamin D3 supplementation improves serum vitamin D levels in chronic liver disease patients and shows associations with improved liver function markers, but high-quality human efficacy trials remain limited. Evidence is moderate: a few human studies show benefits, but sample sizes are small and long-term clinical outcomes are not fully established.

Zinc supplementation shows probable efficacy for liver health, particularly in cirrhosis and NAFLD, with consistent improvements in liver enzymes and ammonia levels across multiple human studies. However, evidence remains limited by small sample sizes, short intervention periods, and lack of replication from independent research groups.

Berberine shows probable efficacy for liver health in humans, particularly for NAFLD and metabolic dysfunction-associated steatotic liver disease, with multiple RCTs and observational studies demonstrating improvements in liver enzyme markers and metabolic parameters. However, evidence remains inconsistent—some large RCTs show null effects on liver fat content and enzyme levels, limiting confidence in clinical meaningfulness.

Curcumin supplementation shows probable efficacy for improving liver enzyme markers (ALT and AST) in patients with nonalcoholic fatty liver disease, supported by multiple meta-analyses of RCTs. However, effect sizes are modest, results are inconsistent across studies, and clinical meaningfulness remains uncertain.

Quercetin shows probable efficacy for liver health based on 6 human RCTs and numerous animal studies, with consistent improvements in liver enzyme markers and oxidative stress indicators. However, effect sizes in humans are modest and most mechanistic evidence derives from animal models, limiting definitive proof of clinical benefit.

CoQ10 supplementation shows probable benefit for liver health markers in humans, with meta-analyses demonstrating modest but statistically significant reductions in liver enzymes (ALT, AST, GGT). However, evidence is limited to small RCTs and observational studies; clinical meaningfulness and long-term efficacy remain incompletely characterized.

Melatonin shows probable efficacy for improving liver health markers in humans, with multiple studies demonstrating reduced liver enzyme levels (ALT, AST, ALP, GGT) and improved antioxidant status. However, evidence is limited to a small number of human trials with modest sample sizes and inconsistent findings across liver function parameters.

Milk thistle (silymarin) shows probable efficacy for liver health in humans, with multiple studies demonstrating improved liver enzyme levels and reduced fatty liver disease markers. However, evidence is limited by lack of large RCTs, inconsistent effect sizes across studies, and mixed results on mortality outcomes in serious liver disease.

Black seed oil shows probable benefit for liver health based on multiple meta-analyses and RCTs, with consistent reductions in liver enzymes (ALP, AST) and improvements in metabolic markers. However, evidence is limited by small sample sizes in individual studies, short intervention durations, and minimal direct liver function testing in most trials.

Green tea extract (EGCG) shows probable efficacy for liver health in humans, with multiple RCTs demonstrating improvements in fatty liver disease and liver enzymes. However, evidence is limited by small sample sizes, short durations, and potential hepatotoxicity at high doses in genetically susceptible individuals.

Spirulina shows probable benefit for liver health in humans, with one small pilot study (n=15) demonstrating significant improvements in liver enzymes and lipid markers in NAFLD patients. However, evidence is limited to a single human observational study; most supporting data comes from animal models and mechanistic reviews.

Fenugreek shows probable benefit for liver health based on limited human evidence and consistent animal/in-vitro findings. Human RCTs demonstrate improvements in liver markers and metabolic parameters, but sample sizes are small and direct hepatoprotective efficacy in humans remains incompletely proven.

Vitamin C shows probable hepatoprotective effects in multiple human observational studies and numerous animal models, with consistent evidence for reducing liver enzymes and improving markers of liver damage. However, no human RCTs exist, limiting definitive proof of efficacy in humans.

Vitamin E shows probable efficacy for liver health in humans with NAFLD, demonstrated by one meta-analysis of RCTs showing statistically significant reductions in liver enzymes and histological improvements. However, evidence is limited to a small number of human trials with modest effect sizes, and mechanistic studies reveal complex hepatic handling that may limit bioavailability in fatty livers.

Chromium supplementation shows probable benefits for liver health markers in humans with metabolic conditions, with multiple RCTs demonstrating reduced liver enzymes (ALT/AST) and improved metabolic parameters. However, evidence is limited by small sample sizes, short study durations, and concerns about potential toxicity at high doses.

Spermidine shows probable efficacy for liver health based on multiple animal studies and a few human observational studies, with consistent effects on fibrosis, steatosis, and viral hepatitis. However, no human RCTs exist, limiting definitive proof of clinical efficacy.

Sulforaphane shows probable efficacy for liver health through multiple mechanistic pathways (Nrf2 activation, antioxidant defense, anti-inflammation), supported by consistent animal data and limited human evidence. However, proof of clinical efficacy in liver disease is incomplete: only 1 human RCT exists (focused on insulin resistance/NAFLD), and most direct liver-protective evidence comes from preclinical models.

Glutathione supplementation shows probable benefit for liver health in humans exposed to hepatotoxic drugs or conditions, with evidence from observational studies and mechanistic animal research demonstrating reduced oxidative stress and improved hepatic function. However, efficacy is not conclusively proven due to limited human RCT data and small sample sizes in available studies.

Boswellia serrata shows probable hepatoprotective effects in humans with type 2 diabetes and in multiple animal models, with consistent improvements in liver enzyme markers and oxidative stress parameters. However, evidence comes from small human studies (n<100) and is predominantly based on animal research; no large, well-controlled RCTs in liver disease populations exist.

Pycnogenol shows probable hepatoprotective effects in animal models of liver injury and oxidative stress, with mechanistic support from biochemical studies. However, evidence in humans is limited to 2 small RCTs without direct liver health outcomes, preventing conclusive proof of efficacy in human liver disease.

Reishi demonstrates probable hepatoprotective effects supported by one human RCT showing improved liver function parameters and multiple animal studies with consistent mechanistic findings. However, efficacy in humans is not conclusively proven due to limited high-quality human data and one case report of potential hepatotoxicity with concurrent alcohol use.

Pterostilbene shows probable efficacy for liver health based on 2 human RCTs and extensive animal evidence, with demonstrated reductions in liver inflammation markers and hepatic steatosis. However, evidence remains limited to small human studies and the primary efficacy endpoint (hepatic fat fraction) was not significantly improved in the largest human trial.

Pomegranate extract shows probable efficacy for liver health, supported by one double-blind human RCT demonstrating improvements in liver enzymes and hepatokines in NAFLD patients, alongside consistent animal evidence. However, efficacy remains unproven for general liver health due to limited human trials and mixed results in some contexts.

Grape seed extract shows probable benefit for liver health, particularly in non-alcoholic fatty liver disease, supported by multiple human RCTs demonstrating improvements in liver enzymes and oxidative stress markers. However, human evidence is limited to small trials (n=25-50) with short durations (2-4 months), and results have not been independently replicated by multiple research groups.

Stinging nettle shows probable benefit for liver health in diabetic patients, with clinical trials demonstrating reduced liver enzyme levels and improved glucose metabolism. However, evidence is limited to small human studies and animal models; robust large-scale RCTs are lacking.

Lemon balm shows probable hepatoprotective effects in humans with diabetes and metabolic disorders, supported by multiple human RCTs demonstrating improvements in liver enzymes and antioxidant markers. However, evidence remains limited by small sample sizes, short treatment durations, and inconsistent effects across liver function parameters.

Schisandra chinensis shows probable hepatoprotective effects supported by one human RCT and multiple animal studies demonstrating reductions in liver enzymes and improvements in lipid profiles. However, human evidence remains limited to a single small RCT with 17 participants, preventing definitive proof of clinical efficacy.

SAMe shows probable efficacy for liver health, particularly for cholestasis and intrahepatic cholestasis, with improvements in liver enzymes and quality of life in humans. However, evidence remains limited by small sample sizes, short durations, and lack of large-scale RCTs demonstrating clinical superiority over existing treatments.

Rapamycin (sirolimus/everolimus) demonstrates probable efficacy for liver health in transplant patients with hepatocellular carcinoma, reducing HCC recurrence and improving survival in multiple human observational studies. However, evidence is limited to transplant populations; efficacy in non-transplant liver disease is not established, and significant metabolic side effects (elevated lipids, liver enzyme elevation) are documented.

Whey protein shows probable benefits for liver health in humans with fatty liver disease, reducing hepatic fat content and improving liver enzyme profiles, but evidence is limited to small-to-moderate RCTs with short durations and inconsistent findings across studies.

Butyrate shows probable efficacy for liver health based on multiple human observational studies and animal models demonstrating improved liver fibrosis, steatosis, and cirrhosis markers. However, evidence is limited to one small RCT and primarily observational data; large, rigorously controlled human trials are lacking.

Betaine supplementation shows promise for liver health, particularly in reducing hepatic steatosis and fibrosis markers in obese populations, but evidence is limited to small pilot human trials and animal studies. Clinical efficacy in liver disease remains probable but not conclusively proven.

Ginkgo biloba shows probable hepatoprotective effects based on multiple animal studies and limited human evidence, but efficacy in humans is not conclusively proven. Human data is sparse (2 observational studies, 1 RCT focused on a non-liver outcome) and most positive evidence comes from rodent models.

Panax ginseng and its ginsenosides show probable hepatoprotective effects in preclinical studies and one small human trial, with consistent improvements in liver enzymes and oxidative stress markers. However, evidence is primarily animal-based with only 1 human RCT, limiting definitive proof of clinical efficacy in liver health.

Vinpocetine shows hepatoprotective effects across multiple animal models and limited human data, primarily through antioxidant and anti-inflammatory mechanisms. However, efficacy is demonstrated mainly in animal studies; human evidence is sparse and lacks large-scale RCTs specific to liver health outcomes.

Acetyl-L-carnitine (ALC) shows probable efficacy for liver health, particularly in hepatic encephalopathy and drug-induced liver injury, based on multiple human RCTs with modest sample sizes and consistent positive results. However, evidence remains limited by small trial sizes and primarily focuses on specific liver conditions rather than general liver health.

Glycine supplementation shows probable benefits for liver health in humans, particularly for reducing liver enzyme markers and improving metabolic dysfunction-associated liver disease (MASLD) indices, but evidence comes from only one small RCT (n=19) and a few observational studies. Animal data consistently support mechanisms involving glutathione synthesis and detoxification pathways.

HMB shows probable efficacy for liver health in cirrhotic patients, with consistent benefits for muscle mass and sarcopenia-related outcomes. However, evidence is limited to small-to-moderate human RCTs (n≤47) with short durations, and clinically meaningful improvements in liver function markers are inconsistent.

BCAAs show probable benefits for liver health in cirrhotic patients, particularly for reducing ascites, improving albumin levels, and potentially reducing hepatic encephalopathy complications. However, efficacy for sarcopenia and mortality remains inconsistent across studies, and the single large RCT found no benefit for muscle strength or lean mass.

Leucine supplementation shows probable benefit for liver health in cirrhosis patients, particularly for sarcopenia and muscle protein synthesis, but evidence is limited to 2 small human RCTs and multiple animal studies. Human efficacy is not conclusively proven.

BPC-157 shows liver protective effects in animal models of ischemia-reperfusion injury and multi-organ failure, but lacks direct human evidence for liver health benefits.

Ashwagandha shows hepatoprotective potential in preclinical models and animal studies, but human evidence for liver health is limited to safety monitoring in non-liver-disease populations and multiple case reports of liver injury. Efficacy for treating liver disease is not established.

Animal and in-vitro studies suggest TB-500 may protect against liver fibrosis by inhibiting hepatic stellate cell activation, but human evidence is limited to observational studies showing altered TB-500 levels in liver disease without proven therapeutic efficacy.

Ipamorelin has been studied in animal models for effects on hepatic nitrogen metabolism and GH/IGF-I signaling, but no human evidence exists to demonstrate efficacy for liver health. Animal studies show modest metabolic effects that are mechanistically relevant but do not establish clinical benefit.

Selank shows hepatoprotective effects in rat models of stress-induced liver damage, reducing morphological degeneration and modulating antioxidant markers. However, no human trials exist, and efficacy in humans remains unproven.

Epithalon shows antioxidant and geroprotective effects in rodent models with a plausible mechanism involving enhanced antioxidant enzyme expression and melatonin production. However, no human clinical trials exist, limiting proof of efficacy for liver health specifically.

DSIP shows hepatoprotective and antioxidant effects in multiple animal models, but evidence is limited to rodent studies with no human efficacy data for liver health. A single human RCT exists but focuses on stroke/myocardial infarction, not liver function.

KPV shows plausible anti-inflammatory and hepatoprotective mechanisms in rat models of stress and endotoxemia, but no human efficacy data exists. All evidence comes from animal studies with small sample sizes.

MOTS-c shows consistent hepatoprotective effects across multiple animal models and observational human studies, but efficacy in humans remains unproven due to the absence of randomized controlled trials. All human evidence is correlational or small observational studies.

SS-31 shows consistent hepatoprotective effects in animal models and cell culture through mitochondrial-targeted antioxidant mechanisms, but no human RCTs exist to prove efficacy in liver health. Evidence is limited to observational studies and animal research.

Kisspeptin shows plausible mechanisms for liver health based on mechanistic studies in animal models and human cell lines, but there is no direct human evidence demonstrating that kisspeptin supplementation improves liver health outcomes. All human data are observational associations with kisspeptin levels rather than intervention studies.

GHRP-2 shows potential hepatoprotective effects in animal models of liver injury and endotoxemia, but evidence is limited to preclinical studies with no human trials demonstrating efficacy for liver health specifically.

GHRP-6 shows plausible effects on liver health through ghrelin receptor modulation in animal models, primarily by regulating hepatic lipid and glucose metabolism. However, no human clinical trials demonstrate efficacy for liver health, and findings are limited to mechanistic studies in rodents and fish.

Hexarelin shows emerging promise for liver health based on animal studies demonstrating reduced hepatic triglycerides and improved lipid metabolism, but no human RCTs or clinical trials have tested efficacy in liver disease or health outcomes.

Melanotan 2 shows consistent metabolic and energy expenditure effects in rodent models, primarily through melanocortin receptor activation in the hypothalamus. However, no human studies exist for liver health specifically, and all evidence comes from animal studies with indirect relevance to hepatic function.

Humanin shows plausible hepatoprotective mechanisms in animal models and theoretical benefits for liver metabolism, but no human clinical trials demonstrate efficacy for liver health. Evidence is limited to animal studies, mechanistic reviews, and a single human RCT focused on neuronal necrosis rather than liver function.

GDF11's effects on liver health are contradictory and context-dependent. While some studies show potential benefits for liver fibrosis and metabolic syndrome, others demonstrate harmful effects on liver regeneration and fibrosis progression. No human RCTs exist, and observational human data are limited and conflicting.

VIP shows mechanistic promise for liver health through anti-inflammatory and hepatocyte proliferation pathways, but evidence is limited to observational human studies of VIPomas (tumors), animal models, and in-vitro work. No human RCTs demonstrate that VIP supplementation improves liver health or outcomes in non-tumor populations.

Vilon shows potential benefits for liver health in animal models of cirrhosis, but efficacy is not proven in humans. All evidence comes from rat studies with small sample sizes and no human trials.

ARA-290 shows hepatoprotective potential in animal models, particularly through anti-inflammatory mechanisms and islet protection during transplantation, but no human clinical trials have directly evaluated liver health outcomes. Evidence is limited to rodent studies and mechanistic research.

Cerebrolysin shows plausible hepatoprotective effects in animal models and a small human observational study, but efficacy for liver health in humans remains unproven. All human evidence is non-randomized and observational with unclear sample sizes.

Ibutamoren shows potential to restore liver function in aging models and GHS-R1a receptor activity in hepatic tissue, but human evidence is limited to two case reports of hepatotoxicity with no demonstrated efficacy for liver health.

Cortexin has not been studied for liver health in humans. Animal studies show that Cortexin (a brain cortex polypeptide) exhibits tissue-specific effects in culture systems, but there is no direct evidence that it improves liver function or health.

Resveratrol shows plausible mechanisms for liver health improvement, but human evidence is weak and inconsistent. Multiple meta-analyses of RCTs found no significant effect on liver enzymes or fat content in general populations, with only subgroup benefits in patients with existing liver disease.

NMN shows promise for liver health primarily through animal studies and mechanistic research demonstrating NAD+ restoration and protection against alcohol-induced fatty liver disease and ischemia-reperfusion injury. However, human efficacy evidence is limited to small observational studies and one small RCT with modest effects, making clinical proof of efficacy still preliminary.

Alpha-lipoic acid shows mechanistic promise for liver health through antioxidant and metabolic effects in animal and cell models, but human evidence is limited and inconsistent. The most rigorous human meta-analysis (2026) found no significant benefit for NAFLD patients across multiple liver health markers.

Collagen peptides show consistent hepatoprotective effects in animal models through antioxidant mechanisms, but evidence in humans is limited to 2 small studies with mixed or indirect liver health outcomes. Efficacy is plausible but not proven in human populations.

Vitamin K2 shows mechanistic promise for liver health through antioxidant and anti-inflammatory pathways in animal models, but human efficacy for liver-specific outcomes remains unproven. Evidence is limited to observational studies in disease states and animal research.

Boron shows promise for liver health in animal models through antioxidant and anti-inflammatory mechanisms, but no human clinical trials exist to establish efficacy in humans. Current evidence is limited to small animal studies and mechanistic research.

Rhodiola rosea components (primarily salidroside) show consistent hepatoprotective effects in animal models through antioxidant and anti-inflammatory mechanisms, but human efficacy for liver health remains unproven—only 3 human observational studies exist, none directly measuring liver outcomes.

Maca root shows hepatoprotective potential in animal models through antioxidant and anti-inflammatory mechanisms, but there is no human clinical evidence demonstrating efficacy for liver health. All robust efficacy data come from rodent studies.

Elderberry has been studied for liver health primarily through mechanistic research and one human RCT showing safety, but there is no proven efficacy for treating or improving liver function in humans. Most evidence is indirect or from animal/in-vitro models.

Aged garlic extract shows hepatoprotective potential in animal models and some immune benefits in advanced cancer patients, but direct evidence of efficacy for liver health in humans is limited to a single small RCT and indirect markers. Most evidence is mechanistic or from animal studies.

Psyllium husk shows promise for liver health through animal studies demonstrating lipid-lowering effects and hepatoprotection, but human evidence is limited to one small RCT in a specific disease state (hepatic encephalopathy). Efficacy in liver health for general populations remains unproven in humans.

Glucosamine + Chondroitin has not been studied for liver health in rigorous human trials. Limited observational evidence suggests potential protective associations in large cohorts, but mechanistic studies reveal glucosamine can promote viral replication and cause acute hepatotoxicity in susceptible individuals.

B vitamin complex may support liver health through multiple metabolic pathways, but evidence is predominantly mechanistic or observational in humans. Only one small RCT directly tested B vitamins for liver outcomes in dairy cows with null results, and human studies lack rigorous RCT designs for liver-specific endpoints.

Vitamin B12 supplementation shows plausible but unproven efficacy for liver health in humans. One RCT in NAFLD patients demonstrated reduced homocysteine and modest improvements in fasting glucose and oxidative stress markers, but failed to show significant between-group differences in liver enzyme levels or hepatic steatosis compared to placebo.

Iron supplementation shows plausible mechanisms for supporting liver health and preventing iron deficiency-related metabolic dysfunction, but direct evidence of hepatoprotective efficacy in humans is limited. Most evidence comes from animal models, mechanistic reviews, and studies in disease-specific populations (dialysis, surgery, cancer) rather than healthy individuals or those with primary liver disease.

Selenium shows plausible hepatoprotective mechanisms in animal models and limited human data, but efficacy for liver health in humans remains unproven. Two small human RCTs showed mixed results—one found no effect on liver enzymes, the other showed improved liver function in cancer patients—insufficient to establish clinical benefit.

Copper is essential for liver health and copper deficiency is documented in liver disease patients, but evidence for copper supplementation improving liver function in healthy individuals or treating liver disease is limited to case reports and small observational studies. No large human RCTs demonstrate clinical efficacy.

Biotin shows a plausible mechanistic role in liver health through its function as a cofactor for carboxylases and biotinidase enzyme activity, but direct evidence of therapeutic benefit for liver disease in humans is limited to observational studies showing reduced biotinidase activity in liver disease patients.

Fisetin shows hepatoprotective properties in cell and animal models through antioxidant and anti-inflammatory mechanisms, but a recent human RCT found senolytics (including fisetin) failed to prevent liver damage progression in MASLD, indicating efficacy in humans remains unproven.

Urolithin A shows plausible hepatoprotective effects in multiple animal models and mechanistic studies, but lacks rigorous human clinical trial evidence. Current data supports further investigation but do not yet prove efficacy in humans.

Astaxanthin shows antioxidant and hepatoprotective effects in animal models and demonstrates some favorable impacts on liver-related metabolic markers, but no human RCT evidence exists to prove efficacy for liver health in humans. Current evidence is limited to animal studies and one meta-analysis showing a paradoxical increase in ALT levels.

TUDCA shows plausible mechanisms for liver protection through ER stress reduction and anti-apoptotic effects, but human evidence is limited and mixed. Only 3 human RCTs exist, with inconsistent results: one showed no benefit for TPN-associated cholestasis, while mechanistic studies suggest potential in NAFLD and acetaminophen toxicity, but these lack robust clinical proof.

Nattokinase shows emerging potential for liver health primarily through indirect mechanisms (lipid reduction, antioxidant effects, hepatotoxin protection), but direct evidence of liver-specific efficacy in humans is absent. Animal studies demonstrate protective effects against liver damage and improved liver function markers, but human evidence is limited to liver safety assessments and indirect lipid/metabolic benefits.

Shilajit extract shows hepatoprotective effects against acetaminophen-induced liver injury in animal models, with significant reductions in liver damage markers. However, no human clinical trials exist, so efficacy in humans remains unproven.

Beta-glucans show immune-modulatory and anti-inflammatory effects in animal models and limited human studies, with one RCT demonstrating improvements in inflammatory markers in overweight subjects. However, direct evidence of efficacy specifically for liver health in humans is lacking; most liver-specific findings come from animal models or mechanistic reviews.

Cordyceps shows plausible hepatoprotective effects through polysaccharides and cordycepin in animal models and in vitro studies, but lacks direct human clinical trials demonstrating efficacy for liver health. Current evidence is insufficient to prove clinical benefit in humans.

Chaga shows hepatoprotective effects in animal and cell culture studies through antioxidant and anti-inflammatory mechanisms, but lacks human clinical trials demonstrating efficacy for liver health. Evidence is emerging but not proven in humans.

Epicatechin shows hepatoprotective potential in animal models and mechanistic studies, but there is no human clinical trial evidence demonstrating efficacy for liver health. Mechanisms are well-characterized, but clinical proof in humans is absent.

Olive leaf extract shows hepatoprotective potential in animal models and limited human studies, but human evidence for liver health remains sparse and inconclusive. Most positive findings come from preclinical studies; human RCTs show no significant effects on liver enzymes.

Bromelain shows hepatoprotective effects in animal models of liver injury through anti-inflammatory and antioxidant mechanisms, but evidence is limited to one small human observational study and three animal studies. Efficacy in humans for liver health remains unproven.

Mucuna pruriens shows hepatoprotective potential in multiple animal models with consistent reversal of liver enzyme elevation and oxidative stress markers, but evidence is limited to animal studies with only 2 small human RCTs that do not directly assess liver health outcomes.

Ecdysterone shows hepatoprotective effects in animal models of metabolic dysfunction, with evidence of reduced liver damage markers and improved lipid profiles. However, direct human evidence for liver health is limited to small preliminary studies, making efficacy in humans unproven.

Turkesterone shows consistent hepatoprotective effects in animal models of liver injury and metabolic dysfunction, but no human clinical trials exist to confirm efficacy in humans. All evidence is from rodent studies conducted primarily in the 1980s-2010s.

Cistanche shows hepatoprotective potential in multiple animal models through antioxidant and anti-inflammatory mechanisms, but efficacy in humans is unproven. Only 1 human observational study exists, which was a mechanistic study of a multi-herb formula, not a dedicated human trial of Cistanche for liver health.

Tribulus terrestris shows potential hepatoprotective effects in animal models and limited human case evidence, but human efficacy for liver health remains unproven. Evidence is primarily from animal studies and case reports of both toxicity and protection.

Echinacea shows promise for liver health through immune-stimulating and antioxidant mechanisms demonstrated in animal models and mechanistic studies, but robust human clinical trial evidence is absent. Efficacy in humans with liver disease remains unproven.

Valerian root shows mechanistic promise for liver health through antioxidant and anti-cancer pathways in animal and in-vitro studies, but human evidence is limited to case reports of hepatotoxicity and one polyherbal formulation RCT that did not assess liver outcomes. No direct human evidence demonstrates efficacy for liver health.

Kava shows anxiolytic efficacy in some human RCTs, but evidence for liver health specifically is limited to safety assessments rather than hepatoprotective benefits. The compound's hepatotoxicity risk—demonstrated in case reports of severe liver injury and transplantation—contradicts any positive liver health indication.

CLA shows potential hepatoprotective effects in animal and in-vitro models, but human evidence is limited and mixed. Multiple meta-analyses of human RCTs found no significant effect on primary liver enzymes (ALT), with only modest reductions in oxidative stress markers (MDA), and one case report of severe acute liver failure requiring transplantation.

Methylene blue shows plausible hepatoprotective potential in animal models and one human case of toxin-induced liver injury, but no rigorous human trials demonstrate efficacy for liver health as a primary outcome.

Astragalus components show hepatoprotective effects in animal and mechanistic studies, with promising results against liver injury, fatty liver disease, and liver cancer. However, human evidence is minimal—only 1 small RCT and 2 observational studies exist, making efficacy in humans unproven.

Lion's Mane shows hepatoprotective potential in animal models and in vitro studies through antioxidant and anti-inflammatory mechanisms, but human evidence for liver health is limited to 3 observational studies with mixed quality and no RCTs demonstrating efficacy.

Alpha-GPC shows consistent protective effects against liver injury in animal models, particularly in ischemia-reperfusion and hypoxic stress scenarios, but no human clinical trials for liver health exist. Efficacy is plausible based on mechanistic evidence but unproven in humans.

Bacopa monnieri shows hepatoprotective effects in multiple animal models of drug and toxin-induced liver injury, with consistent restoration of liver enzyme markers and antioxidant status. However, no human RCTs exist to prove efficacy in humans with liver disease.

Phosphatidylserine (PS) is implicated in liver disease pathogenesis based on observational human studies and animal models, but evidence of therapeutic efficacy for liver health is absent. Studies show PS accumulation or exposure correlates with liver injury, yet no clinical trials demonstrate that PS supplementation improves liver outcomes.

CDP-choline shows plausible mechanisms for liver support through phospholipid metabolism, but human efficacy for liver health remains unproven. Only one human RCT exists (alcohol use disorder), with no liver-specific clinical outcomes demonstrated.

Huperzine A shows hepatoprotective effects in animal models of liver injury, but there is no human clinical trial evidence demonstrating efficacy for liver health. All positive findings come from rodent studies.

PQQ shows consistent protective effects against liver damage and oxidative stress in animal models, primarily through antioxidant and mitochondrial mechanisms. However, no human RCTs directly measuring liver health outcomes exist, limiting evidence to animal studies and mechanistic pathways.

Noopept shows antioxidant and hepatoprotective potential in animal models of diabetes, with evidence of reduced oxidative damage and DNA protection in liver tissue. However, no human clinical trials exist for this goal, and efficacy in humans remains unproven.

Piracetam is not demonstrated to improve liver health in humans. Evidence consists of case reports of liver injury with piracetam (primarily when combined with temozolomide) and a single meta-analysis mentioning piracetam for medication-induced headache, with no direct evidence of hepatoprotective benefit.

Centrophenoxine shows plausible mechanisms for liver health in animal models, primarily through membrane fluidization and lipofuscin removal, but lacks human clinical trials demonstrating efficacy for liver-specific outcomes.

L-theanine shows promise for liver health in animal models through antioxidant and anti-inflammatory mechanisms, but no human clinical trials exist to prove efficacy in humans with liver disease.

L-glutamine shows plausible mechanisms for supporting liver health through ammonia metabolism and glutamine synthetase activity, but efficacy in humans has not been proven. Available evidence is primarily mechanistic and observational; no human RCTs demonstrate clinical benefit for liver disease.

GABA shows plausible mechanisms for supporting liver health through multiple pathways (antioxidant, anti-inflammatory, metabolic regulation), but robust human clinical evidence for direct liver disease treatment is absent. Evidence consists primarily of mechanistic reviews, animal studies, and a single small human observational study.

L-citrulline has not been proven effective for liver health in humans. While some observational studies in patients with urea cycle disorders show it reduces ammonia levels, and one RCT in adolescents with fatty liver disease shows modest improvements in lipid profiles when combined with exercise, the evidence base is too limited and inconsistent to establish efficacy for general liver health.

Taurine shows plausible mechanisms for liver health support through antioxidant and anti-inflammatory actions, but human efficacy for liver disease is not established. Evidence consists primarily of animal studies, mechanistic reviews, and two meta-analyses with inconsistent results on liver-specific outcomes.

L-carnosine shows plausible benefits for liver health through anti-glycation and antioxidant mechanisms in animal models, but no human clinical trials exist to prove efficacy in humans.

L-arginine shows plausible mechanisms for liver health via nitric oxide and antioxidant pathways, but human evidence is limited to small studies and observational data. Animal studies consistently show protective effects against liver injury, but efficacy in humans remains unproven.

Tryptophan shows plausible mechanisms for liver health support through AhR activation and ammonia metabolism modulation, but evidence remains primarily mechanistic and animal-based. Only one small human RCT exists, showing tolerability but not proven clinical efficacy for liver disease.

L-ornithine-L-aspartate shows promise for improving quality of life in cirrhotic patients with hepatic encephalopathy based on one open-label human study, but efficacy is not yet conclusively proven due to lack of placebo control and limited study replication.

L-lysine supplementation shows promise for liver health in animal models of autoimmune hepatitis, but no human clinical trials exist. Evidence is limited to a single mouse study demonstrating protective effects against experimental liver injury.

Creatine monohydrate has been extensively studied for liver safety and consistently shows no adverse hepatic effects, but there is no evidence it actively improves liver function or health.

GHK-Cu has not been tested in any human trials for liver health. Only review articles discuss theoretical hepatic benefits based on mechanistic properties, and one animal study examined copper protection in zebrafish—not liver function specifically.

Sermorelin (GHRH agonist) has no direct evidence for liver health benefit. The available evidence concerns liver as a bystander organ in GH/IGF-I metabolism and cancer research, with no human trials demonstrating hepatoprotective effects.

Dihexa has not been studied for liver health in humans or animals. One study mentions it as a component of a small-molecule cocktail for hepatic cell differentiation from stem cells in vitro, but this is not evidence of liver health benefits in living organisms.

Gonadorelin has not been studied for direct liver health benefits. Abstracts mention liver function tests as safety monitoring parameters in clinical trials, but show no evidence that gonadorelin improves liver health or treats liver disease.

Pinealon's effects on liver health are not addressed in available literature. The single review discusses antihypoxic properties in neuronal models, with no evidence related to hepatic function or liver disease.

Cortagen showed tissue-specific effects on rat liver tissue in culture, but there is no evidence of efficacy in humans or even in living animals. This single in-vitro study does not prove the compound works for liver health.

Cartalax has not been studied for liver health in any published research. The single PubMed abstract retrieved discusses kidney tissue effects in rodents, not liver effects, making this compound irrelevant to the liver health goal.

IGF-1 LR3 has not been studied for liver health; the single available abstract examined its effects on growth and protein synthesis in diabetic rats, with no liver-specific outcomes measured.

MGF has not been studied for liver health in humans or animals. All abstracts discuss MGF's role in muscle growth, repair, and neuroprotection—not hepatic function or liver-specific outcomes.

Prostatilen has not been studied for liver health in humans. A single animal study shows it stimulated cell growth in rat liver tissue cultures, but this preliminary in-vitro finding does not demonstrate efficacy for liver health in any living organism.

Tongkat Ali has not been proven effective for liver health. While some human studies report normal liver function tests during use, one case report documents acute liver injury attributed to the supplement, and animal studies show mixed hepatic effects with no clear benefit to liver health specifically.

Saw palmetto has not been studied for liver health efficacy in humans. The evidence consists entirely of mechanistic studies, enzyme inhibition assays, and isolated case reports of potential liver toxicity, with no demonstrated benefit for liver health in any human trial.

No human evidence demonstrates that iodine supplementation improves liver health. The 20 most relevant abstracts show iodine's role in thyroid function and thyroid hormone metabolism, with incidental observations of liver enzyme abnormalities in thyroid disease states, but no direct liver health outcomes or therapeutic benefits.

DIM shows no proven efficacy for liver health. The evidence consists of animal studies and one human case report demonstrating that DIM may harm liver function through estrogenic effects and altered drug metabolism, with no human RCTs or clinical evidence of liver benefits.

Colostrum has not been studied for liver health outcomes in humans. The available evidence consists entirely of animal studies and mechanistic observations unrelated to liver function, with no demonstrated efficacy for hepatic health in any human population.

No human evidence exists for apigenin's effects on liver health. One animal study shows apigenin as a minor component in a plant extract with hepatoprotective effects, and one in-vitro study demonstrates bioavailability but does not address liver health outcomes.

MSM has not been demonstrated to improve liver health in humans. Available evidence is limited to one small animal study showing modest effects on liver antioxidant enzymes under oxidative stress, and one in-vitro mechanistic study in liver cells with no direct liver health outcome measured.

Lactoferrin for liver health lacks direct human evidence. The available abstracts mention lactoferrin only as a potential protective agent against toxin-induced liver damage in a review context, with no actual efficacy data demonstrating benefit to liver health.

Fadogia agrestis shows evidence of hepatotoxicity rather than liver health benefits in animal studies. A single rat study demonstrated cellular damage to liver tissue through oxidative stress mechanisms, making it unsuitable as a liver-supportive supplement.

Passionflower has not been studied for liver health in the abstracts provided. The available evidence discusses anxiolytic and sedative effects unrelated to hepatic function.

Pregnenolone is not supported by clinical evidence for liver health. The abstracts show pregnenolone or its derivatives used as research tools to induce liver enzyme expression, not as a therapeutic for hepatic disease or protection.

D-Ribose has not been studied directly for liver health in any of the identified abstracts. While one observational review mentions D-ribose as a potential metabolic intervention for heart failure, no clinical evidence demonstrates efficacy for liver-specific outcomes.

Forskolin has not been demonstrated to improve liver health in humans. The only human RCT found no significant liver benefit, while multiple animal studies reveal that Coleus forskohlii extract (CFE) actually induces hepatotoxicity, fatty liver, and dangerous drug-metabolizing enzyme alterations—effects not attributable to forskolin itself.

Peppermint oil has not been studied for liver health in any of the available literature. All identified studies focus on gastrointestinal and IBS outcomes, with no human or animal evidence demonstrating efficacy for hepatic function or liver disease.

Uridine is not directly studied as a liver health intervention in these abstracts. The identified studies focus on uridine metabolism enzymes (UCK2, CMPK2) in hepatocellular carcinoma and HCV treatment with antivirals, not on uridine supplementation for liver health.

DMAE has not been studied for liver health in any human trials. The only relevant finding is a single 1979 animal study showing DMAE reduced paracetamol-induced liver enzyme elevations in rats and mice, but this is insufficient to establish efficacy for liver health as a standalone goal.

No evidence supports sulbutiamine for liver health. The single available study examined benfotiamine (a different thiamine derivative) in animals and did not assess liver health outcomes.

L-Tyrosine has not been studied for liver health efficacy in humans. Available evidence consists of mechanistic studies of tyrosine metabolism in liver tissue and one case report of acute liver failure associated with a supplement containing N-acetyl-L-tyrosine, which does not support therapeutic use.

5-HTP has not been studied for liver health in humans. The available abstracts discuss 5-HTP's use as a diagnostic tracer for neuroendocrine tumors and its effects on serotonin metabolism and other systems, but provide no evidence of efficacy for improving liver function or protecting hepatic tissue.

Beta-alanine has not been studied for liver health in any of the 30 available abstracts. All evidence concerns muscle performance, fatigue, and carnosine metabolism; no studies demonstrate efficacy for hepatic function or liver disease.

D-Aspartic Acid has not been studied for liver health in any meaningful way. The abstracts show D-Aspartic Acid mentioned only as a metabolite biomarker or incidental finding in liver disease research, not as a therapeutic intervention for liver health.